RU2016121542A - Неконкурентные в отношении нейрегулина аллостерические антитела против человеческого her3 и их применения - Google Patents
Неконкурентные в отношении нейрегулина аллостерические антитела против человеческого her3 и их применения Download PDFInfo
- Publication number
- RU2016121542A RU2016121542A RU2016121542A RU2016121542A RU2016121542A RU 2016121542 A RU2016121542 A RU 2016121542A RU 2016121542 A RU2016121542 A RU 2016121542A RU 2016121542 A RU2016121542 A RU 2016121542A RU 2016121542 A RU2016121542 A RU 2016121542A
- Authority
- RU
- Russia
- Prior art keywords
- seq
- paragraphs
- antibody
- region
- sequence represented
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (24)
1. Неконкурентное в отношении нейрегулина аллостерическое антитело против человеческого HER3, содержащее тяжелую цепь, где вариабельный домен содержит:
- H-CDR1, обладающую по меньшей мере 90% или 95% идентичностью с последовательностью, представленной как SEQ ID NO: 2,
- H-CDR2, обладающую по меньшей мере 90% или 95% идентичностью с последовательностью, представленной как SEQ ID NO: 3,
- H-CDR3, обладающую по меньшей мере 90% или 95% идентичностью с последовательностью, представленной как SEQ ID NO: 4,
- L-CDR1, обладающую по меньшей мере 90% или 95% идентичностью с последовательностью, представленной как SEQ ID NO: 6,
- L-CDR2, обладающую по меньшей мере 90% или 95% идентичностью с последовательностью, представленной как SEQ ID NO: 7,
- L-CDR3, обладающую по меньшей мере 90% или 95% идентичностью с последовательностью, представленной как SEQ ID NO: 8, и
которое специфично связывается с HER3 с по существу такой же аффинностью, как и антитело, содержащее тяжелую цепь, где вариабельный домен содержит SEQ ID NO: 2 для H-CDR1, SEQ ID NO: 3 для H-CDR2 и SEQ ID NO: 4 для H-CDR3, и легкую цепь, где вариабельный домен содержит SEQ ID NO: 6 для L-CDR1, SEQ ID NO: 7 для L-CDR2 и SEQ ID NO: 8 для L-CDR3.
2. Антитело по п. 1, содержащее вариабельную область тяжелой цепи, содержащую SEQ ID NO: 2 в области H-CDR1, SEQ ID NO: 3 в области H-CDR2 и SEQ ID NO: 4 в области H-CDR3; и вариабельную область легкой цепи, содержащую SEQ ID NO: 6 в области L-CDR1, SEQ ID NO: 7 в области L-CDR2 и SEQ ID NO: 8 в области L-CDR3.
3. Антитело по п. 1, где вариабельная область тяжелой цепи указанного антитела имеет аминокислотную последовательность, представленную как SEQ ID NO: 1, и/или вариабельная область легкой цепи имеет аминокислотную последовательность, представленную как SEQ ID NO: 5.
4. Антитело по п. 1, представляющее собой химерное антитело, предпочтительно химерное мышиное/человеческое антитело.
5. Антитело по п. 1, представляющее собой гуманизированное антитело.
6. Фрагмент антитела по любому из пп. 1-5.
7. Фрагмент по п. 6, содержащий цепь VL или VH.
8. Фрагмент по п. 6, выбранный из группы, состоящей из Fv, Fab, F(ab')2, Fab', dsFv, scFv, sc(Fv)2 и диател.
9. Нуклеотидная последовательность, кодирующая антитело по любому из пп. 1-5 или фрагмент по любому из пп. 6-8.
10. Нуклеотидная последовательность, кодирующая тяжелую цепь или легкую цепь моноклонального антитела по любому из пп. 1-5.
11. Нуклеотидная последовательность по п. 10, представляющая собой SEQ ID NO: 9 или SEQ ID NO: 10.
12. Вектор, содержащий нуклеиновую кислоту по п. 10 или 11.
13. Клетка-хозяин, содержащая нуклеиновую кислоту по п. 10 или 11, или вектор по п. 12.
14. Фармацевтическая композиция, содержащая антитело по любому из пп. 1-5 или его фрагмент по любому из пп. 6-8.
15. Антитело по любому из пп. 1-5 или его фрагмент по любому из пп. 6-8 для применения в качестве лекарственного средства.
16. Способ лечения рака у субъекта, включающий введение субъекту антитела по любому из пп. 1-5 или его фрагмента по любому из пп. 6-8.
17. Антитело по любому из пп. 1-5 или его фрагмент по любому из пп. 6-8 для применения в диагностике рака.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2013/002733 WO2015067986A1 (en) | 2013-11-07 | 2013-11-07 | Neuregulin allosteric anti-her3 antibody |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2016121542A true RU2016121542A (ru) | 2017-12-12 |
RU2704228C2 RU2704228C2 (ru) | 2019-10-24 |
Family
ID=50193544
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2016121542A RU2704228C2 (ru) | 2013-11-07 | 2013-11-07 | Неконкурентные в отношении нейрегулина аллостерические антитела против человеческого her3 и их применения |
Country Status (12)
Country | Link |
---|---|
US (1) | US10196455B2 (ru) |
EP (1) | EP3066124B1 (ru) |
JP (1) | JP6449876B2 (ru) |
KR (1) | KR20160101909A (ru) |
CN (1) | CN105849125B (ru) |
BR (1) | BR112016010336A2 (ru) |
CA (1) | CA2929386C (ru) |
ES (1) | ES2865196T3 (ru) |
MX (1) | MX2016005854A (ru) |
PL (1) | PL3066124T3 (ru) |
RU (1) | RU2704228C2 (ru) |
WO (1) | WO2015067986A1 (ru) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3091033A1 (en) * | 2015-05-06 | 2016-11-09 | Gamamabs Pharma | Anti-human-her3 antibodies and uses thereof |
TW201716439A (zh) | 2015-07-20 | 2017-05-16 | 美國禮來大藥廠 | Her3抗體 |
US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
US11326182B2 (en) | 2016-04-29 | 2022-05-10 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
KR20200031571A (ko) * | 2017-05-29 | 2020-03-24 | 가마맵스 파마 | 암 연관 면역억제의 억제제 |
EA202092458A1 (ru) * | 2018-04-11 | 2021-02-08 | Салюбрис Байотерапьютикс, Инк. | Композиции на основе рекомбинантного слитого белка, содержащего нейрегулин-1 (nrg-1) человека, и способы их применения |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4486414A (en) | 1983-03-21 | 1984-12-04 | Arizona Board Of Reagents | Dolastatins A and B cell growth inhibitory substances |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
EP0247091B1 (en) | 1985-11-01 | 1993-09-29 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
US4816444A (en) | 1987-07-10 | 1989-03-28 | Arizona Board Of Regents, Arizona State University | Cell growth inhibitory substance |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
WO1989012624A2 (en) | 1988-06-14 | 1989-12-28 | Cetus Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
US5076973A (en) | 1988-10-24 | 1991-12-31 | Arizona Board Of Regents | Synthesis of dolastatin 3 |
EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US4978744A (en) | 1989-01-27 | 1990-12-18 | Arizona Board Of Regents | Synthesis of dolastatin 10 |
US4879278A (en) | 1989-05-16 | 1989-11-07 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15 |
US4986988A (en) | 1989-05-18 | 1991-01-22 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13 |
SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
US5138036A (en) | 1989-11-13 | 1992-08-11 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14 |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
IL101943A0 (en) | 1991-05-24 | 1992-12-30 | Genentech Inc | Structure,production and use of heregulin |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
EP0640094A1 (en) | 1992-04-24 | 1995-03-01 | The Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US6034065A (en) | 1992-12-03 | 2000-03-07 | Arizona Board Of Regents | Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10 |
US5410024A (en) | 1993-01-21 | 1995-04-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
JP3866760B2 (ja) | 1993-02-22 | 2007-01-10 | ザ ロックフェラー ユニバーシティ | 一過性トランスフェクションによる高力価のヘルパーフリーのレトロウイルスの生産 |
JPH08511420A (ja) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | 抗 体 |
FR2712812B1 (fr) | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition pour la production de produits thérapeutiques in vivo. |
KR100261941B1 (ko) | 1994-07-13 | 2000-07-15 | 나가야마 오사무 | 사람의 인터루킨-8에 대한 재구성 사람항체 |
US5504191A (en) | 1994-08-01 | 1996-04-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide methyl esters |
US5521284A (en) | 1994-08-01 | 1996-05-28 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides and esters |
US5530097A (en) | 1994-08-01 | 1996-06-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory peptide amides |
US5554725A (en) | 1994-09-14 | 1996-09-10 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Synthesis of dolastatin 15 |
US5599902A (en) | 1994-11-10 | 1997-02-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Cancer inhibitory peptides |
US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
EP0811691B1 (en) | 1995-09-11 | 2004-12-01 | Kyowa Hakko Kogyo Co., Ltd. | Antibody againts alpha-chain of human interleukin 5 receptor |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
US6130237A (en) | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
WO1998036765A1 (en) | 1997-02-25 | 1998-08-27 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18 |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
EP0971952A2 (en) | 1997-04-10 | 2000-01-19 | Royal Netherlands Academy of Arts and Sciences | Diagnosis method and reagents |
WO1998052976A1 (en) | 1997-05-21 | 1998-11-26 | Biovation Limited | Method for the production of non-immunogenic proteins |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
KR100940380B1 (ko) | 1999-01-15 | 2010-02-02 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
EP2270147B2 (en) | 1999-04-09 | 2020-07-22 | Kyowa Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
US6323315B1 (en) | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
KR100787073B1 (ko) | 2000-06-28 | 2007-12-21 | 글리코파이, 인크. | 변형된 당단백질의 제조방법 |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US20030083263A1 (en) | 2001-04-30 | 2003-05-01 | Svetlana Doronina | Pentapeptide compounds and uses related thereto |
PL213948B1 (pl) | 2001-10-25 | 2013-05-31 | Genentech Inc | Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje |
EP2357006B1 (en) | 2002-07-31 | 2015-09-16 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
AU2005249396B2 (en) | 2004-05-05 | 2011-10-20 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents for modulating biological activity |
KR20070114765A (ko) | 2005-02-23 | 2007-12-04 | 메리맥 파마슈티컬즈, 인크. | 생물학적 활성을 조절하기 위한 이특이성 결합제 |
AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
PT2129396E (pt) * | 2007-02-16 | 2013-11-18 | Merrimack Pharmaceuticals Inc | Anticorpos contra erbb3 e suas utilizações |
AR075896A1 (es) | 2009-03-20 | 2011-05-04 | Genentech Inc | Anticuerpos anti-her (factor de crecimiento epidermico) |
EP2233500A1 (en) | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Optimized Fc variants |
CN103890010B (zh) * | 2011-05-19 | 2017-04-19 | 法国国家健康医学研究院 | 抗‑人‑her3抗体及其用途 |
-
2013
- 2013-11-07 EP EP13834359.5A patent/EP3066124B1/en active Active
- 2013-11-07 RU RU2016121542A patent/RU2704228C2/ru active
- 2013-11-07 KR KR1020167015132A patent/KR20160101909A/ko not_active Application Discontinuation
- 2013-11-07 BR BR112016010336A patent/BR112016010336A2/pt not_active IP Right Cessation
- 2013-11-07 US US15/035,129 patent/US10196455B2/en active Active
- 2013-11-07 CA CA2929386A patent/CA2929386C/en active Active
- 2013-11-07 JP JP2016528182A patent/JP6449876B2/ja active Active
- 2013-11-07 PL PL13834359T patent/PL3066124T3/pl unknown
- 2013-11-07 MX MX2016005854A patent/MX2016005854A/es unknown
- 2013-11-07 WO PCT/IB2013/002733 patent/WO2015067986A1/en active Application Filing
- 2013-11-07 CN CN201380081577.3A patent/CN105849125B/zh active Active
- 2013-11-07 ES ES13834359T patent/ES2865196T3/es active Active
Also Published As
Publication number | Publication date |
---|---|
JP2016536988A (ja) | 2016-12-01 |
CA2929386C (en) | 2023-01-03 |
US20160319033A1 (en) | 2016-11-03 |
CN105849125A (zh) | 2016-08-10 |
ES2865196T3 (es) | 2021-10-15 |
BR112016010336A2 (pt) | 2017-10-03 |
EP3066124A1 (en) | 2016-09-14 |
RU2704228C2 (ru) | 2019-10-24 |
KR20160101909A (ko) | 2016-08-26 |
WO2015067986A1 (en) | 2015-05-14 |
PL3066124T4 (pl) | 2021-08-16 |
MX2016005854A (es) | 2017-07-28 |
JP6449876B2 (ja) | 2019-01-09 |
EP3066124B1 (en) | 2021-01-06 |
US10196455B2 (en) | 2019-02-05 |
PL3066124T3 (pl) | 2021-08-16 |
CA2929386A1 (en) | 2015-05-14 |
CN105849125B (zh) | 2020-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2014101707A (ru) | АНТИ-Axl АНТИТЕЛА И ИХ ПРИМЕНЕНИЕ | |
HRP20192280T1 (hr) | Anti-ceacam6 protutijela i njihova uporaba | |
RU2018133708A (ru) | Антитела, обладающие специфичностью к btla, и их использование | |
RU2016100892A (ru) | Антитела против tweakr и их применение | |
IL265434B2 (en) | Anti-CD27 antibodies | |
HRP20170568T1 (hr) | Protutijela anti-ox40 i postupci za njihovu uporabu | |
RU2016121542A (ru) | Неконкурентные в отношении нейрегулина аллостерические антитела против человеческого her3 и их применения | |
PH12018502623A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
JP2020500003A5 (ru) | ||
ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
JP2020522261A5 (ru) | ||
PE20142041A1 (es) | Anticuerpos anti-il-36r | |
JP2017149720A5 (ru) | ||
NZ598202A (en) | High affinity human antibodies to human angiopoietin-2 | |
HRP20231514T1 (hr) | Monoklonska antitijela za faktor rasta i diferencijacije 15 (gdf-15), te njihova uporaba za liječenje tumorske kaheksije i raka | |
MY173334A (en) | Antibodies that bind to tl1a and their uses | |
NZ599438A (en) | Humanized antibodies against human il-22ra | |
MY188237A (en) | Anti-pd-l1 antibodies and uses thereof | |
JP2016536988A5 (ru) | ||
RU2016107814A (ru) | Новое антитело к tslp-рецептору человека | |
RU2014127287A (ru) | Антитела, используемые для пассивной вакцинации против гриппа | |
RU2018100824A (ru) | Антитела, которые связываются с сортилином и подавляют связывание програнулина | |
RU2022101369A (ru) | Анти-met антитела и их использование | |
JP2016530223A5 (ru) | ||
MX2017004970A (es) | Anticuerpos que se unen a ccr6 y sus usos. |